Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

23 févr. 2026 07h10 HE | Source: C4 Therapeutics, Inc.

C4 Therapeutics to Participate in Upcoming March Conferences

WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD)...
23 févr. 2026 07h00 HE | Source: C4 Therapeutics, Inc.

C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma

Enrollment for Phase 2 MOMENTUM Trial Expected to Be Completed in Q1 2027 Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026 WATERTOWN, Mass., Feb. 23,...
09 févr. 2026 16h01 HE | Source: C4 Therapeutics, Inc.

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...
04 févr. 2026 07h00 HE | Source: C4 Therapeutics, Inc.

C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD)...
26 janv. 2026 16h01 HE | Source: C4 Therapeutics, Inc.

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...
14 janv. 2026 07h00 HE | Source: C4 Therapeutics, Inc.

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways

Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 µg Cemsidomide Phase 1b Trial in Combination With Elranatamab On Track to Initiate in Q2 2026 ...
25 nov. 2025 07h00 HE | Source: C4 Therapeutics, Inc.

C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

WATERTOWN, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...
06 nov. 2025 07h00 HE | Source: C4 Therapeutics, Inc.

C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Completed Equity Offering Resulted in $125 Million in Gross Proceeds, Extending Runway to End of 2028, Beyond Key Value Inflection Points; Potential to Earn up to an Additional $225 Million in...
16 oct. 2025 07h08 HE | Source: C4 Therapeutics, Inc.

C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering

$125 Million in Upfront Proceeds Expected to Fund Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 Trial in Combination with Dexamethasone and Phase 1b Trial in...
01 oct. 2025 07h00 HE | Source: C4 Therapeutics, Inc.

C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma

WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...

Page suivante